Sublingual semaglutide offered to UK practices despite Novo Nordisk concerns
An unlicensed semaglutide-based product that is administered under the tongue is being marketed to private doctors in the…
Novo Nordisk starts €432m Ireland facility upgrade for oral Wegovy production
Novo Nordisk has invested €432m ($501m) to upgrade its facility in Ireland to ensure the drugmaker can meet…
Novo sues Hims & Hers despite Wegovy pill offering U-turn
Hims & Hers has abandoned plans to sell a compounded version of Novo Nordisk’s Wegovy (semaglutide) pill, though…